Reported a net loss of $590,489 for the three months ended March 31, 2026, compared to a net loss of $587,259 in the same period of 2025. Generated zero revenue for the quarter, consistent with the prior year period. Total operating expenses were $589,229, primarily driven by research and development costs of $117,064 and general and administrative expenses of $262,149. Cash balance as of March 31, 2026, was $180, down from $14,774 at year-end 2025. Total liabilities reached $2,563,889, with significant amounts owed to related party Sanovas. The company requires approximately $7,000,000 in additional capital to fund product development and operations.